Share this article
Share this article
ResearchAndMarkets.com s offering.
The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient s immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy.
Search jobs FDA Approves Amgen s RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan
® (rituximab), for the treatment of adult patients with Non-Hodgkin s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021. The approval of RIABNI represents an important milestone across our biosimilar and oncology portfolios, said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. Following the proven success of KANJINTI
Amgen today announced that the U.S. Food and Drug Administration has approved RIABNI™ a biosimilar to Rituxan ® for the treatment of adult patients with Non-Hodgkin’s Lymphoma Chronic Lymphocytic Leukemia Granulomatosis with Polyangiitis and Microscopic Polyangiitis . RIABNI will be made available in the U.S. in January 2021 . “The approval of RIABNI represents an important milestone across our biosimilar and …
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021 .
Global CAR-T Cell Therapy Market Size, Analysis, Competitive Strategies and Forecasts by 2026 marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.